Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07342972

Gastrointestinal Symptoms and Tolerance in Infants Fed Goat or Cow's Milk-based Infant Formula

This randomized controlled double-blind study will compare the effect of a commercially available goat milk formula to a cow's milk formula on gastrointestinal symptoms and tolerance, and infections in infants.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

14 day–90 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

King Faissal Specialist Hospital & Research Centre

Riyadh, Saudi Arabia

Location contact

Abdullah Aldowaish, Dr.

CONTACT

[email protected]

0555878540

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 14 days and 90 days.
  • Healthy singleton term infants born between 37 weeks and 42 weeks of gestation.
  • Infants who have received CMF for at least 7 consecutive days.
  • Exclusive formula feeding.
  • Cow's Milk-related Symptoms Score (CoMiSS®) value at baseline of ≥6 and <10.
  • Parents' or caregivers, aged ≥18 years, willing to give informed consent and adhere to study protocol

Exclusion criteria

  • Exclusively or partially feeding with human milk
  • Introduced to solid food, supplementary feeding, use of pre- and/or probiotics as a supplement
  • Congenital or recurrent chronic conditions and/or malabsorption that could interfere with study parameters.
  • Diagnosed cow's milk allergy (CMA) or suspected to have CMA, soy allergy, fish allergy, egg allergy and/or lactose intolerance.
  • Receiving medication (on own initiative or prescription) with regard to FGID (i.e. reflux medication)
  • Sibling already participating in this study
  • Participation in another clinical trial

Treatment and study plan

Goat milk-based infant formula

Other

Study product is administered on demand until the age of 6 months.

Cow's milk-based infant formula

Other

Study product is administered on demand until the age of 6 months.

Primary outcomes

  1. Gastrointestinal symptoms as determined by CoMiSS

    Time frame: Difference between groups at Day 14 of the intervention

    The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms).

  2. Gastrointestinal tolerance as determined by IGSQ

    Time frame: Difference between groups at the end of the intervention at 24 weeks

    The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress.

Secondary outcomes

  1. Gastrointestinal symptoms throughout the study as determined by CoMiSS

    Time frame: From enrollment to the end of the intervention at 24 weeks

    The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms).

  2. Gastrointestinal tolerance throughout the study as determined by IGSQ

    Time frame: From enrollment to the end of the intervention at 24 weeks

    The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress.

  3. Occurrence, duration and severity of gastrointestinal infections as determined by Vesikari

    Time frame: From enrollment to the end of the intervention at 24 weeks

    The Vesikari Clinical Severity Scoring System includes a e-diary card completed by parents, to identify rotavirus gastroenteritis episodes. The Vesikari Clinical Severity Scoring System Parameters score ranges from 0 to 20 with score <7 as mild symptoms and score 10 to 20 as severe symptoms.

  4. Occurrence, duration and severity of respiratory infections as determined by CARIFS

    Time frame: From enrollment to the end of the intervention at 24 weeks

    Canadian Acute Respiratory Illness and Flu Scale is a validated parental questionnaire, to measure the disease severity of children with acute respiratory illness (ARI) including influenza. CARIFS consists of 18 items covering three domains; symptoms (e.g., cough); function (e.g., play), and parental impact (e.g., clinginess). Each item is scored 0 to 3, with higher scores indicating greater severity of illness. The full scale ranges from 0 to 58. For children older than 5 years the full scale is used; for children younger than 5 years, 3 items (headache, sore throat, and muscle aches) are not used for assessment.

  5. Occurrence, duration and severity of ear infections as determined by AOM-SOS V5

    Time frame: From enrollment to the end of the intervention at 24 weeks

    The Acute Otitis Media Symptom Severity scale (AOM-SOS) Version 5.0 is psychometric scale used to measure the severity of symptoms in children with acute otitis media and has been validated for parent-reported use. A 6-point Likert scale ranging from 'No' to 'An extreme amount' is used to rate the presence of 5 symptoms related to acute otitis media over the preceding 24 hours. The AOM-SOS Version 5.0 total score is obtained by summing the scores on these 5 equally-weighted questions.

  6. Quality of life as determined by PedsQL

    Time frame: From enrollment to the end of the intervention at 24 weeks

    The Pediatric Quality of Life Inventory (PedsQL™) Infant Scales™ is a specific module of the PedsQL™. The objective of this validated questionnaire is to measure generic health-related quality of life in infants. Applicable for infants with acute and chronic health conditions and healthy infants. The questionnaire is composed of 36 items comprising 5 dimensions: physical functioning, physical symptoms, emotional functioning, social functioning and cognitive functioning. Higher scores means better HRQOL and fewer problems or symptoms. A 5-point Likert scale from is applied: 0 (Never) to 4 (Almost always). Scores are transformed on a scale from 0 to 100.

  7. Quality of life as determined by WHOQoL-BREF

    Time frame: From enrollment to the end of the intervention at 24 weeks

    The World Health Organization Quality of Life Questionnaire BREF (WHOQoL-BREF) is the shortened version of the WHOQoL-100. The WHOQoL-BREF measures quality of life within the context of an individual's culture, value systems, personal goals, standards of concerns. The measuring instrument consists of 26 items. The raw scoreis transformed to a 0-100 scale, where higher scores indicate higher perceived quality of life.

  8. Weight

    Time frame: From enrollment to the end of the intervention at 24 weeks

    Weight will be measured in kilograms.

  9. Height

    Time frame: From enrollment to the end of the intervention at 24 weeks

    Height will be measured in centimeters.

  10. Head circumference

    Time frame: From enrollment to the end of the intervention at 24 weeks

    Head circumference will be measured in centimeters.

  11. WHO z-scores

    Time frame: From enrollment to the end of the intervention at 24 weeks

    Subject's weight, length and head circumference will be used to calculate the WHO z-scores for weight-for-age, length-for-age, head circumference-for-age, weight-for-length.

  12. Fecal parameters

    Time frame: Baseline, Day 14, Day 28, Week 12 and Week 24

    The major fecal bacterial groups are defined using 16S RNA sequencing. Further fecal parameters (e.g. pH, SCFA, sIgA, A1AT) are determined with standard laboratory techniques.

  13. Sleep and Crying episodes

    Time frame: Baseline, Day 14, Day 28, Week 12 and Week 24

    Sleep and crying episodes and duration are recorded for 24 hours prior to the visits in diaries.

  14. Stool frequency & consistenty

    Time frame: Baseline, Day 14, Day 28, Week 12 and Week 24

    Stool frequency and consistency are recorded for 24 hours prior to visits in diaries.

Study contacts

Contact information is provided by the study sponsor or research team.

Jildou Visser, BSc

CONTACT

[email protected]

+31885015283

Sponsors and collaborators

Lead sponsor

Ausnutria Hyproca B.V.

Industry

Registry information

Official study title

Effect of a Goat-milk Based Infant Formula on Gastrointestinal Symptoms and Tolerability in Healthy Term Infants: a Double-blind Randomized Controlled Trial

Acronym: MESK-2

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 15, 2026
Registry last updated
Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.